Psilocybin is being investigated as a treatment for obsessive–compulsive disorder (OCD), with early findings suggesting that symptoms can sometimes diminish rapidly. The central clinical question is whether a brief change in experience can lead to sustained freedom from compulsions and a meaningful improvement in everyday functioning.
Psilocybin remains an experimental approach to OCD. Small studies provide a reason for further investigation, but they do not establish a dependable response rate, an optimal treatment schedule or superiority to established psychological and pharmacological care.
On this page
- Understanding the symptoms being treated
- What a useful treatment would change
- Why psilocybin is being investigated
- Early clinical findings
- The 2026 repeated-treatment trial
- How this fits with established OCD treatment
- Support without reinforcing compulsions
- Medication, adverse effects and continuing care
- The questions that determine clinical value
Understanding the symptoms being treated
OCD involves intrusive, unwanted thoughts, images or urges, together with repetitive behaviours or mental acts that a person feels compelled to perform. Compulsions may be visible, such as repeated checking, or largely internal, such as reviewing, counting or seeking a particular sense of certainty. The disorder is defined by distress, time consumed and interference with life, rather than by a preference for order or cleanliness.1
The immediate relief associated with a ritual can make it increasingly difficult to resist. Treatment therefore concerns the relationship between distress and the response to it. A person may recognise that a fear is excessive while still feeling unable to stop checking. Intellectual understanding alone is not always enough to interrupt that pattern.
Intrusive thoughts also need to be distinguished from intentions. An unwanted thought can be distressing precisely because it conflicts with the person’s values. Assessment should establish the nature of the experience and evaluate risk individually, rather than infer intent from disturbing content alone. NICE specifically cautions that some common obsessional themes can be misinterpreted as indicating risk.2
What a useful treatment would change
Improvement means more than feeling calmer for several hours. Clinically meaningful change could include spending less time on rituals, tolerating uncertainty, returning to work or education, participating in relationships and recovering activities previously organised around avoidance. Residual intrusive thoughts can persist even when a person’s life is substantially less restricted.
The Yale–Brown Obsessive Compulsive Scale (Y-BOCS) is widely used to quantify symptom severity. A reduction on this scale can indicate treatment response, but response and remission are different categories. Neither automatically establishes recovery across all areas of functioning or freedom from later relapse. Results need to be interpreted alongside the patient’s own priorities and the duration of improvement.
| Clinical change | Why it matters | What should also be assessed |
|---|---|---|
| Lower symptom score | Suggests reduced overall symptom burden. | Magnitude, persistence and any remaining disability. |
| Less distress during a session | May make a difficult experience more tolerable. | Symptoms after the drug has worn off. |
| Fewer compulsions | Can release time and reduce disruption. | Whether covert rituals or avoidance have replaced them. |
| Greater participation in life | Reflects a functional outcome meaningful to the person. | Whether improvement persists through ordinary stress and uncertainty. |
Why psilocybin is being investigated
Psilocybin is converted to psilocin, a serotonergic psychedelic whose effects involve the 5-HT2A receptor. It can alter perception, emotion, attention and the experience of self. This is a different intervention from the sustained administration of a selective serotonin reuptake inhibitor (SSRI); the fact that both involve serotonin does not make their mechanisms or clinical effects interchangeable.34
One proposed therapeutic possibility is that a temporary change in habitual processing allows a less rigid response to intrusive experiences. Research on brain connectivity and plasticity provides a biological context for that hypothesis. It does not establish that OCD is caused by a single abnormal network, or that a psychedelic session resets that network into a healthy state.56
A mechanism must ultimately explain the clinical outcome. If altered experience is helpful, the important question is how it changes behaviour when the person is again confronted by doubt, distress or a trigger for ritualising. The vividness of a session is not itself evidence that this change has occurred.
Early clinical findings
A 2006 study involving nine patients found acute reductions in OCD symptoms after psilocybin administration. It used a small, modified double-blind design with repeated exposures and was primarily informative about feasibility and initial response. The findings did not establish a reliable dose–response relationship or long-term efficacy. One participant experienced transient hypertension.7
A 2025 pharmacological challenge study enrolled 19 adults, of whom 18 completed the assessments. Participants received a very low dose followed four weeks later by a higher dose, always in that order, with psychological support. The higher dose produced greater improvement at one week, particularly in compulsions; the effect diminished over the following three weeks. No benefit was detected on the depression scale used. Because treatment order was fixed rather than randomised, time, expectations and prior experience could contribute to the difference.8
These observations are relevant because they suggest a possible rapid effect without demonstrating a durable cure. They also show why improvement in OCD should not simply be inferred from improvement in mood, or vice versa. Related symptom domains need separate measurement.
The 2026 repeated-treatment trial
A randomised study allocated 15 participants to higher-dose psilocybin, lower-dose psilocybin or lorazepam as an active placebo, with five people in each group. During the first phase, participants received four weekly sessions. In the second phase, every group was offered four higher-dose psilocybin sessions. Next-day scores favoured the psilocybin groups, whereas the main between-group comparison of next-week scores was not statistically significant. A pooled analysis of the two psilocybin groups supported a reduction over the controlled phase. These mixed findings and very small groups require caution.9
At the end of the eight-week treatment period, 73.3% of the 15-person analysis met the study’s response threshold of at least a 35% Y-BOCS reduction, and 40% met its remission criterion. By then, all groups had entered the psilocybin phase. These percentages are not eight-week psilocybin-versus-placebo response rates.9
Benefits diminished during follow-up, although improvement remained for some participants at six months. The study reported no serious adverse events or psychotic symptoms. Neither finding resolves longer-term effectiveness or uncommon harms in a wider population. The treatment also involved repeated supported sessions, so its results cannot be transferred to a single unsupervised exposure.9
The distinction between a controlled comparison and subsequent follow-up is fundamental. Once everyone receives the active intervention, later improvement may still be clinically important, but the original comparator no longer answers how much of that improvement the drug caused. Larger trials need to preserve meaningful comparisons over the period relevant to patients.
How this fits with established OCD treatment
Established treatment includes cognitive behavioural therapy incorporating exposure and response prevention (ERP), and medication such as an SSRI. NICE recommends matching treatment intensity to functional impairment and using combined psychological and pharmacological treatment for severe impairment. Before describing OCD as resistant, assessment should examine whether previous treatment was adequate and whether barriers prevented full participation.2
ERP involves approaching relevant triggers in a planned therapeutic context while reducing the compulsive response. Its purpose is not to prove that nothing distressing can ever happen. The aim is to reduce the extent to which rituals and avoidance govern behaviour. That distinction is particularly relevant when discussing psychedelics, which can create a powerful but temporary feeling of certainty.
A future role for psilocybin might involve improving a person’s ability to engage with established therapy. That remains a hypothesis requiring direct testing. Existing symptom reductions do not demonstrate that adding ERP after a psychedelic session is superior to properly delivered ERP alone, nor do they show which patients would benefit from such a combination.
Support without reinforcing compulsions
Clinical support needs to be sensitive to the ways OCD seeks reassurance. Repeatedly assuring someone that a feared possibility is impossible may briefly reduce distress while becoming part of the ritual. A treatment setting should therefore have a coherent understanding of the person’s symptoms, rather than treat all anxiety as something that must immediately be removed.
During altered consciousness, unusual thoughts or images can feel exceptionally significant. Their emotional force does not verify their truth. An apparent revelation about danger, guilt or responsibility should not be accepted as factual merely because it occurred during a psychedelic experience. Discussion afterwards should allow uncertainty and avoid turning the experience into a new requirement for checking or interpretation.10
This creates an important distinction between validation and endorsement. A clinician can acknowledge that an experience was frightening or meaningful without confirming the belief attached to it. Equally, a patient should not be pressured to describe benefit, discover a hidden cause or adopt a particular spiritual interpretation.
Medication, adverse effects and continuing care
Many people considering experimental treatment already take medication that helps them function. Stopping an SSRI solely to pursue psilocybin can introduce withdrawal symptoms or recurrence of illness. Decisions about continuation, tapering or interaction risk require the treating prescriber and a protocol-specific assessment; there is no universal medication rule that can safely be applied to every patient.11
Acute psilocybin effects can include anxiety, nausea, headache and transient increases in blood pressure. Screening for relevant medical illness and psychiatric vulnerability, together with trained supervision and follow-up, forms part of clinical research safety practice.1213 Small, selected trials cannot establish safety for patients excluded because of instability or other risks.
Follow-up should assess OCD symptoms, sleep, mood, functioning and any troubling changes in beliefs or perception. A short period of relief may be followed by renewed symptoms, which needs a practical response. Recurrence should not be interpreted as failure to integrate the experience correctly or as evidence that another psychedelic session is automatically indicated.
The questions that determine clinical value
The next stage of research needs larger samples, credible comparisons and follow-up long enough to measure relapse. It must clarify whether repeated treatment adds benefit, which outcomes remain improved and how much support is required. Functional outcomes and patient priorities should accompany symptom scales.
Other questions remain unresolved: whether benefit differs across symptom presentations, whether existing medication changes the balance of benefit and harm, and whether the approach improves engagement with established therapy. Research also needs to identify people who experience no benefit or deteriorate, rather than describe only favourable responses.
Psilocybin has a plausible and increasingly testable place in OCD research. Its clinical promise rests on the possibility of reducing the hold of compulsions over everyday life. At present, that possibility is supported by preliminary findings rather than a sufficiently established treatment pathway.
References
- National Institute of Mental Health. Obsessive-Compulsive Disorder (OCD). Health information; accessed 11 October 2026.
- National Institute for Health and Care Excellence. Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31). Recommendations; accessed 11 October 2026.
- Nichols DE. Psychedelics. Pharmacol Rev. 2016;68:264–355. doi:10.1124/pr.115.011478.
- Otto ME, van der Heijden KV, Schoones JW, et al. Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc Analysis. Clin Pharmacokinet. 2025;64:53-66. doi:10.1007/s40262-024-01454-4.
- Siegel JS, Subramanian S, Perry D, et al. Psilocybin desynchronizes the human brain. Nature. 2024;632:131-138. doi:10.1038/s41586-024-07624-5.
- de Vos CMH, Mason NL, Kuypers KPC. Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. Front Psychiatry. 2021;12:724606. doi:10.3389/fpsyt.2021.724606.
- Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67:1735–1740. doi:10.4088/jcp.v67n1110.
- Pellegrini L, Fineberg NA, O’Connor S, et al. Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study. Compr Psychiatry. 2025;142:152619. doi:10.1016/j.comppsych.2025.152619.
- Moreno FA, Allen KE, Wiegand CB, et al. A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder. J Psychopharmacol. 2026;40:837-849. doi:10.1177/02698811261424214.
- McGovern HT, Grimmer HJ, Doss MK, et al. An Integrated theory of false insights and beliefs under psychedelics. Commun Psychol. 2024;2:69. doi:10.1038/s44271-024-00120-6.
- Halman A, et al. Drug–drug interactions involving classic psychedelics: A systematic review. J Psychopharmacol. 2024. doi:10.1177/02698811231211219.
- Yerubandi A, et al. Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2024;7:e245960. doi:10.1001/jamanetworkopen.2024.5960.
- Johnson MW, Richards WA, Griffiths RR. Human Hallucinogen Research: Guidelines for Safety. J Psychopharmacol. 2008;22:603–620. doi:10.1177/0269881108093587.